BioCure Appoints New Director

 In News 2018

Vancouver, British Columbia – April 2nd, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) is pleased to announce that effective April 1st, 2018, Mr. Marco Nonni has joined the board of directors of Biocure Technology Inc.

Ms. Anna Dalaire is resigning from the Board effective immediately. The Board would like to thank Ms. Dalaire for her tenure with the Company and her efforts with ushering it through the change of business. She will continue working with the Company on a consulting basis.

Mr, Nonni will be a valued addition to Biocure bringing over 16 years of experience with Biotech and top ten Pharmaceuticals companies in business development activities in the life science industry. He will be focusing on building key partnership for the advancement of  the company.

Throughout his career, he has have provided leadership and management within Clinical Development for medical and scientific support to products within assigned therapy areas such as Oncology, Cardiovascular, Metabolic, and Rare Genetic Disorders. In addition, he has also supported the development and execution of medical and clinical strategies for assigned products. Mr. Nonni has overseen Clinical and Regulatory cycle and data generation, including medical monitoring, from Phase I-IV clinical research programs ensuring that requirements (from regulatory authorities, stakeholders, and quality standards) were met.

The Company has granted to Mr. Nonni an aggregate of 125,000 options for a two-year term at an exercise price of $1.09 per share with 25,000 options vesting immediately and the balance on April 1st, 2019.

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions.  Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ “Sang Mok Lee”

      CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7149

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.